![](https://voice.ons.org//sites/default/files/2020-05/FDA-Update-700_11_6.jpg)
FDA Approves Neoadjuvant and Adjuvant Durvalumab for Resectable Non-Small Cell Lung Cancer
On August 15, 2024, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi®) with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery, for adults with resectable (tumors that are 4 cm or larger or node positive) non-small cell lung cancer and no known epidermal growth factor receptor variants or anaplastic lymphoma kinase rearrangements.